Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Boldione is a synthetic anabolic androgenic steroid (AAS) and a direct precursor (prohormone) to the anabolic steroid boldenone. Chemically known as androsta-1,4-diene-3,17-dione or androstadienedione, it features double bonds at positions 1 and 4 of the steroid nucleus with keto groups at positions 3 and 17. Boldione is used industrially as a precursor for various steroid hormones in the estrane and androstane classes[1][2][6]. In humans or animals it can be metabolized into boldenone after administration[6][7]. It has been advertised for its anabolic/androgenic effects such as promoting muscularity and enhancing strength[7], but there are no approved medical indications for its use in humans[2]. Boldione acts primarily by serving as a prohormone to boldenone; both compounds exert their effects through activation of the androgen receptor leading to increased protein synthesis and muscle growth[8]. The drug is banned by sports authorities including WADA due to its performance-enhancing potential[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on boldione.